Clinical Trial Update: Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating whether an immune-oncology therapy given every three months after six months of standard administration is as effective as continu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Hepatocellular Carcinoma
• Lung Cancer
• Melanoma
• Merkel Cell Carcinoma
• Renal Cell Carcinoma
• Triple-negative Breast Cancer
• Urothelial Carcinoma

Snippet

Sponsor: UNICANCER | Conditions: Lung Cancer Metastatic, Renal Cell Carcinoma | Phase 3 | Status: RECRUITING